Table 4. The pooled OR of p16INK4A and p14ARF promoter methylation with clinicopathological features in RCC.
| Gene | Studies | Overall OR (95 CI %) | I2; P | P value | M (n) | RCCsmale | M (n) | RCCsfemale | P (Egger test) |
|---|---|---|---|---|---|---|---|---|---|
| p14ARF | 3 | 0.48 (0.25 - 0.94) | 29.1%; 0.238 | 0.032 | 41 | 168 | 25 | 76 | 0.769 |
| p16INK4A | 4 | 0.66 (0.31 - 1.38) | 2.5%; 0.392 | 0.266 | 20 | 201 | 13 | 91 | 0.715 |
| Grade1-2 | Grade 3-4 | ||||||||
| p14ARF | 3 | 2.13 (0.96 - 4.75) | 17.5%; 0.297 | 0.063 | 40 | 111 | 15 | 72 | 0.613 |
| p16INK4A | 7 | 1.20 (0.58 - 2.45) | 0.0%; 0.620 | 0.625 | 41 | 212 | 13 | 102 | 0.644 |
| Stage1-2 | Stage 3-4 | ||||||||
| p14ARF | 1 | 1.03 (0.18 - 5.98) | NA; NA | 0.97 | 6 | 35 | 2 | 12 | NA |
| p16INK4A | 4 | 1.00 (0.42 - 2.36) | 0.0%; 0.786 | 0.999 | 25 | 104 | 11 | 52 | 0.211 |
| pT2-4 | pT1 | ||||||||
| p14ARF | 4 | 0.92 (0.44 - 1.91) | 7.4%; 0.356 | 0.815 | 16 | 94 | 41 | 180 | 0.229 |
| p16INK4A | 6 | 2.43 (1.10 - 5.35) | 0.0%; 0.615 | 0.028 | 28 | 132 | 12 | 203 | 0.36 |
| Node+ | Node- | ||||||||
| p14ARF | 2 | 0.35 (0.04 - 2.83) | 0.0%; 0.665 | 0.326 | 0 | 11 | 23 | 123 | NA |
| p16INK4A | 5 | 0.69 (0.18 - 2.69) | 0.0%; 0.465 | 0.595 | 1 | 18 | 43 | 225 | 0.02 |
| CCRCC | Non-CCRCC | ||||||||
| p14ARF | 4 | 0.38 (0.18 - 0.81) | 0.0%; 0.607 | 0.012 | 34 | 185 | 25 | 100 | 0.294 |
| p16INK4A | 7 | 0.54 (0.29 - 1.00) | 0.0%; 0.842 | 0.051 | 53 | 289 | 31 | 144 | 0.015 |
M: methylation; ccRCC: clear cell renal cell carcinoma; NA: not applicable; Node+: lymph node-positive status; Node-: lymph node-negative status; RCC: renal cancer carcinoma; pT: pathological T category of primary tumor; n: the number of samples; OR: odds ratio; 95% confidence interval (95% CI).